On December 25, Gelonghui (688670.SH) announced that the equipment for the “New Quaternary Influenza Virus Cracking Workshop Project” has all been put in place, and several rounds of commissioning have been carried out in the early stages. It was originally planned to reach the intended useable state in January 2024. Later, due to the external epidemic, the temporary shutdown of the company, etc., the project commissioning and verification work lagged behind the original plan, and a new round of debugging and verification was needed. GMP verification and drug administration department inspection are lagging behind the original plan. While the investment content, total investment amount, and implementation entity of the fund-raising project remain unchanged, it was decided, after scientific evidence, to adjust the date for the fund-raising project “New Quadrivalent Influenza Virus Cleavage Plant Project” to reach its intended useable status to April 2026.
Innovative vaccine research and development projects are mainly research and development of new vaccine products. The company's comprehensive testing progress, company funding status, resource matching and other factors have steadily promoted product research and development. Currently, the project investment progress is 25%. While maintaining the investment content, total investment amount, and implementation entity of the fund-raising project, it was decided to postpone the “innovative vaccine research and development project”. According to the company's manpower, capital and other resources, and in line with the progress of project development and testing, the specific project delivery time is determined according to the actual implementation progress of the project.